NEXTGEN HEALTHCARE, INC (NXGN)
(Delayed Data from NSDQ)
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.75 USD
+0.51 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NextGen (NXGN)-InstaMed Ink Deal to Improve Payment Processing
by Zacks Equity Research
NextGen's (NXGN) latest expanded deal with InstaMed is expected to significantly simplify payment methods for both patients and providers.
Earnings Preview: Nextgen Healthcare (NXGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
iRhythm Technologies (IRTC) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NextGen Healthcare (NXGN) Unveils Health Data Hub Insights
by Zacks Equity Research
NextGen Healthcare's (NXGN) newly launched tool can help healthcare providers to receive a complete picture of the community and patient health.
NextGen Healthcare's (NXGN) Solutions Selected by MHHC
by Zacks Equity Research
NextGen Healthcare's (NXGN) solutions get chosen by MHHC that can help serve the latter's rapidly growing community efficiently.
NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.
Nextgen Healthcare (NXGN) Q4 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -5% and 0.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Surges 7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Phreesia (PHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lineage Cell (LCTX) delivered earnings and revenue surprises of -500% and 56.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nextgen Healthcare (NXGN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enovis (ENOV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 8.82% and 177.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 20.83% and 7.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
The Joint (JYNT) Buys Northern California Regional Developer Zone
by Zacks Equity Research
The Joint (JYNT) expects the Northern California region to hold 75 clinics, including its right to oversee 56 franchisee clinics.
Select Medical (SEM) to Open 31-Bed Hospital in Northern Ohio
by Zacks Equity Research
The new facility is likely to be a satellite unit of Select Medical Holdings' (SEM) Regency Hospital Toledou, located in Sylvania, OH.
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.